M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)

Condition:   Malignant Neoplasm of Breast Interventions:   Drug: M7824 - patients with Stage II or III HER2+ breast cancer;   Drug: Chemotherapy Sponsors:   M.D. Anderson Cancer Center;   EMD Serono Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials